Compare Repligen Corporation Common Stock (RGEN) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs VF Corp — how do they compare? Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B), while VF Corp trades at $16.38 (market cap $6.32B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and VF Corp pays a 2.24% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and VF Corp for 64 Days on average.
| RGEN | VFC | |
|---|---|---|
Market Cap | $11.14B | $6.32B |
Volume | 1,259,263 | 14,983,623 |
Sector | Health | Consumer Cyclical |
52-Week High | $194.57 | $21.55 |
52-Week Low | $102.87 | $12.62 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $11.02B | $10.60B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VFC trades at $16.48, up 4.37% today, with a bullish technical signal and a consensus analyst price target of $18.33. Recent earnings show mixed results, with a Q4 2025 beat but Q1 and Q2 2026 misses. Revenue declined to $9.5B in 2025, with a net loss of $189.72M, though 2026 projects a return to profitability. The company maintains a strong gross margin of 54.97% but faces challenges from high debt and weak performance in its Vans brand.
The outlook is cautiously optimistic, supported by valuation discounts (P/S 0.67) and growth in outdoor brands, but execution risk on the Vans turnaround and high leverage pose significant threats. Near-term price action is buoyed by technical momentum, yet fundamental recovery hinges on sustained revenue improvement and debt reduction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
